| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.01 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |